Kiromic BioPharma Inc Aktie News

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (N...

HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients.

HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial.

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company's Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamm...

HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cel...

HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC Markets' Life Science Investor Forum in a Fireside Chat format, hosted by Virt...

HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouraging clinical findings from the most recent follow-up visit of the first patient enrolled in Deltacel-01, the Company's Phase 1 clinical trial evaluating Deltacel™ for the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC). After stable disease a...

HOUSTON--(BUSINESS WIRE)---- $KRBP #Celltherapy--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01 clinical trial with Deltacel™ for treating stage 4 metastatic non-small cell lung cancer (NSCLC). Favorable preliminary evidence demonstrates Deltacel's efficacy in controlling the ...